IDEAYA Biosciences (NASDAQ:IDYA) Issues Quarterly Earnings Results

Key Points

• IDEAYA Biosciences reported a quarterly EPS loss of $1.22, missing analysts’ estimate of a $1.18 loss. Revenue reached $10.24 million, above the $7.58 million consensus and up 14.6% year over year.
• Shares traded at $31.77, while the company reported negative profitability metrics, including a 75.93% net margin and a 16.73% return on equity.
• Wall Street’s overall view remains favorable, with a consensus “Moderate Buy” rating and a $50.55 target price; however, CEO Yujiro Hata recently sold approximately $985,000 worth of shares.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) announced its earnings results on Tuesday. The company reported ($1.22) earnings per share for the quarter, missing analysts' consensus estimates of ($1.18) by ($0.04), Zacks reports. IDEAYA Biosciences had a negative return on equity of 16.73% and a negative net margin of 75.93%. The company had revenue of $10.24 million during the quarter, compared to the consensus estimate of $7.58 million. During the same period in the prior year, the firm posted $1.33 earnings per share. The company's revenue was up 14.6% on a year-over-year basis.

IDEAYA Biosciences Price Performance

Shares of IDYA stock traded up $0.13 during trading hours on Tuesday, reaching $31.77. The company had a trading volume of 212,560 shares, compared to its average volume of 1,018,937. The company has a 50 day moving average of $37.08 and a 200 day moving average of $34.08. The firm has a market cap of $2.79 billion, a price-to-earnings ratio of -16.33 and a beta of -0.04. IDEAYA Biosciences has a 1-year low of $26.81 and a 1-year high of $42.68.

Insider Transactions at IDEAYA Biosciences

In related news, CEO Yujiro Hata sold 26,338 shares of the stock in a transaction that occurred on Tuesday, October 6th. The shares were sold at an average price of $37.41, for a total value of $985,304.58. Following the sale, the chief executive officer directly owned 690,695 shares in the company, valued at $25,838,899.95. This trade represents a 3.67% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 4.70% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on IDYA. Citizens Jmp reissued a "market outperform" rating and issued a $42.00 price target on shares of IDEAYA Biosciences in a report on Tuesday, September 1st. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of IDEAYA Biosciences in a report on Thursday, October 15th. William Blair initiated coverage on IDEAYA Biosciences in a report on Friday, October 16th. They set an "outperform" rating on the stock. Mizuho set a $44.00 target price on IDEAYA Biosciences in a research note on Thursday. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of IDEAYA Biosciences in a research report on Tuesday, September 22nd. Thirteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, IDEAYA Biosciences currently has an average rating of "Moderate Buy" and a consensus target price of $50.55.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc NASDAQ: IDYA is a biotechnology company focused on discovering and developing precision medicines for cancer. Its research emphasizes synthetic lethality, biomarker-driven drug discovery and molecularly defined patient populations, with the goal of matching targeted therapies to specific genetic alterations in tumors.

The company's pipeline includes darovasertib, an investigational protein kinase C inhibitor being studied primarily for genetically defined cancers, including metastatic uveal melanoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.